Article Details
Retrieved on: 2022-03-01 07:30:56
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
We are initiating with CTI BioPharma with a buy rating with a TP of USD 7.6 if Pacritinib is approved. If FDA delays, I am planning to buy the dip ...
Article found on: seekingalpha.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here